0001104659-16-125231.txt : 20160603 0001104659-16-125231.hdr.sgml : 20160603 20160603072936 ACCESSION NUMBER: 0001104659-16-125231 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20160602 FILED AS OF DATE: 20160603 DATE AS OF CHANGE: 20160603 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Strongbridge Biopharma plc CENTRAL INDEX KEY: 0001634432 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981130690 STATE OF INCORPORATION: L2 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37569 FILM NUMBER: 161694190 BUSINESS ADDRESS: STREET 1: 900 NORTHBROOK DRIVE, SUITE 200 CITY: TREVOSE STATE: PA ZIP: 19053 BUSINESS PHONE: (610) 254-9200 MAIL ADDRESS: STREET 1: 900 NORTHBROOK DRIVE, SUITE 200 CITY: TREVOSE STATE: PA ZIP: 19053 FORMER COMPANY: FORMER CONFORMED NAME: Cortendo AB DATE OF NAME CHANGE: 20150219 6-K 1 a16-12745_16k.htm 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934

 

For the month of June 2016

 

Commission File Number:  001-37569

 

STRONGBRIDGE BIOPHARMA plc

(Exact name of Registrant as specified in its charter)

 

900 Northbrook Drive

Suite 200

Trevose, PA 19053

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x   Form 40-F o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

 

 

 


 

On June 2, 2016, Strongbridge Biopharma plc (the “Registrant”) issued a press release announcing that Matthew Pauls, president and chief executive officer, is scheduled to present at the Jefferies 2016 Healthcare Conference, taking place June 7-10, 2016, in New York City.

 

The presentation will be webcast live and available on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com

 

The information contained in the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any of the Registrant’s registration statements or other filings with the Commission.

 

Exhibits

 

Exhibit
Number

 

Exhibit Table

 

 

 

99.1

 

Press Release issued by Strongbridge Biopharma plc, dated June 2, 2016.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

Dated: June 3, 2016

STRONGBRIDGE BIOPHARMA PLC

 

 

 

 

 

By:

/s/ Stephen Long

 

 

Stephen Long

 

 

Chief Legal Officer

 

3

 EX-99.1 2 a16-12745_1ex99d1.htm EX-99.1

Exhibit 99.1

 

 

Strongbridge Biopharma plc Announces Presentation at Jefferies 2016 Healthcare Conference

 

DUBLIN, Ireland and TREVOSE, Pa., June 2, 2016 — Strongbridge Biopharma plc (NASDAQ:SBBP), a global rare disease biopharmaceutical company focused on the development and commercialization of novel therapeutic options, today announced that management will be presenting at the Jefferies 2016 Healthcare Conference, taking place June 7-10 at the Grand Hyatt in New York City.

 

Matthew Pauls, president and chief executive officer of Strongbridge Biopharma, will provide a corporate overview on Friday, June 10th at 11:00 a.m. ET. The presentation will be webcast live and archived on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.

 

About Strongbridge Biopharma

 

Strongbridge Biopharma is a global rare disease biopharmaceutical company focused on the development and commercialization of novel therapeutic options. Strongbridge’s lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor currently being studied in the global Phase 3 SONICS trial for the treatment of endogenous Cushing’s syndrome. Strongbridge’s rare endocrine disease franchise also includes COR-005, a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing’s disease and neuroendocrine tumors. Both COR-003 and COR-005 have received orphan designation from the U.S. Food and Drug Administration and the European Medicines Agency. For more information, visit www.strongbridgebio.com.

 

Contacts:

 

Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com

 

Investor Relations
The Trout Group
Marcy Nanus

 


 

+1 646-378-2927
mnanus@troutgroup.com

 

USA
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. +1 610-254-9200
Fax. +1 215-355-7389

 

 GRAPHIC 3 g127451mmi001.jpg GRAPHIC begin 644 g127451mmi001.jpg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end